07.20.18
Headquarters: Brentford, Middlesex, UK
twitter.com/GSK
www.gsk.com
Headcount: 99,300
Year Established: 2000
Revenues: $40,725 (+7%)
Pharma Revenues: $30,270 (+8%)
Net Income: $5,514 (+57%)
R&D: $6,039 (+23%)
TOP SELLING DRUGS
GlaxoSmithKline (GSK) reported pharma revenues of $30 billion in 2017. This is an 8% growth over the previous year driven by strong performances from HIV medicines Tivicay and Triumeq, the Ellipta portfolio and Nucala, a biologic medicine for respiratory conditions.
In terms of pipeline progress, towards the end of 2017 GSK received approvals for three key new products: Shingrix, a new vaccine which represents a new standard for the prevention of shingles; Juluca, the first in a series of 2-drug regimens for HIV that reduces the number of drugs patients take as they are now living longer with what is becoming a more chronic disease; and Trelegy Ellipta, which is the first once a day inhaler to combine three medicines in one device to treat chronic obstructive pulmonary disease (COPD).
Manufacturing network facelift
GSK has made several moves recently designed to improve its manufacturing network. These include both investments for respiratory and HIV medicines manufacturing in the UK, the sale of several products and the closure of a UK manufacturing site.
Between now and 2020, the company said it plans to invest more than $185 million at its Ware, Hertfordshire, Barnard Castle, Co. Durham and Montrose, Scotland sites. The investments will support expansion of manufacturing for respiratory and HIV medicines. This new investment is in addition to the $360 million announced last year and an investment of more than $1.6 billion in UK manufacturing since 2012.
As part of the initiative, GSK is reviewing its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The company has also decided to outsource some manufacturing activity at its Worthing site in the UK. GSK will continue to manufacture other antibiotics such as Augmentin and will continue to research new antibiotics. The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity.
In its consumer healthcare business, GSK reached an agreement in March 2018 with Novartis for the buyout of Novartis’ stake in their consumer healthcare joint venture for $13 billion. GSK is looking to possibly sell its Horlicks and its other consumer healthcare nutrition products to support funding of the transaction.
The majority of Horlicks and other nutrition product sales are generated in India, with the Horlicks range is widely recognized as a portfolio of premium nutrition products. On the heels of the Novartis deal, GSK said it was planning to close its Horlicks factory in Slough, UK.
GSK expects the outcome of the strategic review to be concluded around the end of 2018. It says India remains a priority market for GSK investment and growth. For the pharmaceutical and vaccines businesses, GSK is looking to build new manufacturing capacity in Vemgal, Karnataka and Nashik.
During the year GSK also divested its anaesthesia portfolio to Aspen Pharmacare, a move also aligned with GSK’s strategy of simplification through focusing on core therapeutic areas. It also sold a consumer healthcare manufacturing facility in Aiken, SC to contract development and manufacturing organization (CDMO) Avara Pharmaceutical Services.
Drug discovery driven
Plasticell, a biotechnology company specializing in stem cell screening and cell therapies, entered into a collaboration with GSK for the use of its stem cell screening technology, CombiCult, to optimize induced pluripotent stem cells (iPSCs) to specific blood cell lineages for GSK’s therapeutic research. Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK to identify and optimize iPSC differentiation protocols.
Also, UK Biobank announced a major research initiative with GSK and the Regeneron Genetics Center (RGC) to generate genetic sequence data from the 500,000 volunteer participants in the UK Biobank resource. The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases. The groundbreaking UK/US initiative will deliver first data within a year.
GSK selected a third target under its ongoing oncology discovery collaboration with Immunocore for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers. This is the third program to be initiated as part of the discovery collaboration from 2013. Immunocore is currently working on two other ImmTAC programs under the agreement. The lead program is on track for an investigational new drug (IND).
Finally, a strategic drug discovery collaboration with Exscientia will apply its AI enabled platform to discover novel and selective small molecules for up to 10 disease-related targets nominated by GSK across multiple therapeutic areas. Exscientia will apply both its Big Data resources comprising medicinal chemistry and large-scale bioassays, and its AI-driven algorithms to design novel molecules that fulfill the requirements of the lead and candidate criteria.
twitter.com/GSK
www.gsk.com
Headcount: 99,300
Year Established: 2000
Revenues: $40,725 (+7%)
Pharma Revenues: $30,270 (+8%)
Net Income: $5,514 (+57%)
R&D: $6,039 (+23%)
TOP SELLING DRUGS
Drug | Indication | 2017 Sales | (+/-%) |
Seretide/Advair | asthma, COPD | $4,069 | 0% |
Triumeq | HIV | $3,199 | 58% |
Tivicay | HIV | $1,825 | 64% |
Ventolin | asthma | $997 | 9% |
Infanrix, Pediarix | pediatric vaccine | $966 | 8% |
Lamictal | anti-epileptic | $845 | 18% |
Avodart | enlarged prostate | $796 | 7% |
Flixotide/Flovent | respiratory | $775 | 4% |
Augmentin | antibacterial | $763 | 16% |
Boostirx | adult vaccine | $728 | 14% |
GlaxoSmithKline (GSK) reported pharma revenues of $30 billion in 2017. This is an 8% growth over the previous year driven by strong performances from HIV medicines Tivicay and Triumeq, the Ellipta portfolio and Nucala, a biologic medicine for respiratory conditions.
In terms of pipeline progress, towards the end of 2017 GSK received approvals for three key new products: Shingrix, a new vaccine which represents a new standard for the prevention of shingles; Juluca, the first in a series of 2-drug regimens for HIV that reduces the number of drugs patients take as they are now living longer with what is becoming a more chronic disease; and Trelegy Ellipta, which is the first once a day inhaler to combine three medicines in one device to treat chronic obstructive pulmonary disease (COPD).
Manufacturing network facelift
GSK has made several moves recently designed to improve its manufacturing network. These include both investments for respiratory and HIV medicines manufacturing in the UK, the sale of several products and the closure of a UK manufacturing site.
Between now and 2020, the company said it plans to invest more than $185 million at its Ware, Hertfordshire, Barnard Castle, Co. Durham and Montrose, Scotland sites. The investments will support expansion of manufacturing for respiratory and HIV medicines. This new investment is in addition to the $360 million announced last year and an investment of more than $1.6 billion in UK manufacturing since 2012.
As part of the initiative, GSK is reviewing its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The company has also decided to outsource some manufacturing activity at its Worthing site in the UK. GSK will continue to manufacture other antibiotics such as Augmentin and will continue to research new antibiotics. The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity.
In its consumer healthcare business, GSK reached an agreement in March 2018 with Novartis for the buyout of Novartis’ stake in their consumer healthcare joint venture for $13 billion. GSK is looking to possibly sell its Horlicks and its other consumer healthcare nutrition products to support funding of the transaction.
The majority of Horlicks and other nutrition product sales are generated in India, with the Horlicks range is widely recognized as a portfolio of premium nutrition products. On the heels of the Novartis deal, GSK said it was planning to close its Horlicks factory in Slough, UK.
GSK expects the outcome of the strategic review to be concluded around the end of 2018. It says India remains a priority market for GSK investment and growth. For the pharmaceutical and vaccines businesses, GSK is looking to build new manufacturing capacity in Vemgal, Karnataka and Nashik.
During the year GSK also divested its anaesthesia portfolio to Aspen Pharmacare, a move also aligned with GSK’s strategy of simplification through focusing on core therapeutic areas. It also sold a consumer healthcare manufacturing facility in Aiken, SC to contract development and manufacturing organization (CDMO) Avara Pharmaceutical Services.
Drug discovery driven
Plasticell, a biotechnology company specializing in stem cell screening and cell therapies, entered into a collaboration with GSK for the use of its stem cell screening technology, CombiCult, to optimize induced pluripotent stem cells (iPSCs) to specific blood cell lineages for GSK’s therapeutic research. Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK to identify and optimize iPSC differentiation protocols.
Also, UK Biobank announced a major research initiative with GSK and the Regeneron Genetics Center (RGC) to generate genetic sequence data from the 500,000 volunteer participants in the UK Biobank resource. The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases. The groundbreaking UK/US initiative will deliver first data within a year.
GSK selected a third target under its ongoing oncology discovery collaboration with Immunocore for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers. This is the third program to be initiated as part of the discovery collaboration from 2013. Immunocore is currently working on two other ImmTAC programs under the agreement. The lead program is on track for an investigational new drug (IND).
Finally, a strategic drug discovery collaboration with Exscientia will apply its AI enabled platform to discover novel and selective small molecules for up to 10 disease-related targets nominated by GSK across multiple therapeutic areas. Exscientia will apply both its Big Data resources comprising medicinal chemistry and large-scale bioassays, and its AI-driven algorithms to design novel molecules that fulfill the requirements of the lead and candidate criteria.